MyopiaX Treatment for the Reduction of Myopia Progression in Children and Adolescents: Safety and Efficacy Investigation (MyopiaX-1)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04967287 |
Recruitment Status :
Active, not recruiting
First Posted : July 19, 2021
Last Update Posted : February 20, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Myopia | Device: MyopiaX Device: Myopia control spectacles | Not Applicable |
The present study is a multicentric, randomized, controlled, single masked trial to investigate the signals of effect, the safety and tolerability of MyopiaX in slowing the progression of myopia.
The trial consists of 12 months treatment period. The first 6 months participants will be treated either with MyopiaX or with myopia control spectacles. During the second half of the trial, participants treated with MyopiaX will receive the myopia control spectacles in addition. 81 children and adolescent aged 6 - 12 years will be included in the trial. Eligible subjects will be randomly assigned in a 2:1 ratio to either the MyopiaX or the myopia control spectacles group.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 124 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | MyopiaX Treatment for the Reduction of Myopia Progression in Children and Adolescents: Safety and Efficacy Investigation |
Actual Study Start Date : | November 16, 2021 |
Estimated Primary Completion Date : | April 30, 2024 |
Estimated Study Completion Date : | November 30, 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: MyopiaX
MyopiaX treatment
|
Device: MyopiaX
MyopiaX treatment twice a day |
Active Comparator: Myopia control spectacles
Clinically validated treatment to control myopia
|
Device: Myopia control spectacles
To be used all as prescribed |
- Change in axial length and in spherical equivalent refractive error [ Time Frame: 6 months ]Change in axial length (mm) and in spherical equivalent refractive error )D)from baseline to month 6.
- Change in axial length and in spherical equivalent refractive error [ Time Frame: 12 months ]Change in axial length (mm) and spherical equivalent refractive error (D) from month 6 to month 12
- Retinal and choroidal imaging parameters [ Time Frame: 12 months ]Retinal and choriodal parameters during the course of the trial
- Device usability as measured with the user feedback questionnaire [ Time Frame: 12 months ]Device usability as measured with the user feedback questionnaire at the end of the study
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 6 Years to 12 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Myopic children (-0.75 to -5.0 D SER, least myopic meridian -0.50 D in each eye)
- At least VA 0.2 LogMAR in each eye
- Age: 6 - 12 years old
- Good tolerability of test session with VR system
- Binocular adequacy as tested with VR
- Ability to understand treatment and give valid assent
Exclusion Criteria:
- Concomitant or previous therapies for myopia
- Eye diseases/conditions:
- Anisometropia ≥ 1.5 D
- Astigmatism ≥ 3 D
- Ophthalmological comorbidities
- Optic nerve abnormalities
- Suspicion of syndromic or monogenetic myopia
- Systemic illnesses affecting eye health, eye growth, and/or refraction
- Any illnesses affecting dopamine function (e.g., sleep disorder)
- Medication affecting dopamine function, accommodation, pupil size, or having an impact on the ocular surface (such as allergy medications)
- Participation in other clinical studies
- Medical history (or family history) of photosensitive epilepsy
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04967287
Germany | |
Suedblick GmbH | |
Augsburg, Germany | |
MVZ Makula-Netzhaut-Zentrum Breyer Kaymak Klabe | |
Düsseldorf, Germany, 40549 | |
BeyondEye Clinic | |
Köln, Germany | |
University Medical Center, Johannes Gutenberg- University | |
Mainz, Germany | |
University Eye Hospital Tübingen | |
Tübingen, Germany | |
Netherlands | |
Erasmus University Medical Center | |
Rotterdam, Netherlands | |
Portugal | |
University of Minho | |
Braga, Portugal | |
Spain | |
Hospital Sant Joan de Déu | |
Barcelona, Spain | |
University Complutense of Madrid | |
Madrid, Spain | |
United Kingdom | |
Moorfields Eye Hospital NHS Fundation Trust | |
London, United Kingdom |
Study Chair: | Ian Flitcroft, Prof. | Centre for Eye Reserach Ireland, Technological University Dublin |
Responsible Party: | Dopavision GmbH |
ClinicalTrials.gov Identifier: | NCT04967287 |
Other Study ID Numbers: |
MyopiaX-1 |
First Posted: | July 19, 2021 Key Record Dates |
Last Update Posted: | February 20, 2024 |
Last Verified: | September 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Digital treatment |
Myopia Refractive Errors Eye Diseases |